Teva Pharmaceutical Industries (NYSE:TEVA) Given New $30.00 Price Target at UBS Group

Teva Pharmaceutical Industries (NYSE:TEVAGet Free Report) had its price objective increased by investment analysts at UBS Group from $28.00 to $30.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group’s price objective suggests a potential upside of 36.39% from the stock’s current price.

Other research analysts have also issued research reports about the company. Barclays boosted their price target on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Finally, Piper Sandler upped their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average target price of $22.63.

View Our Latest Stock Analysis on TEVA

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $22.00 on Thursday. The company has a market cap of $24.92 billion, a P/E ratio of -25.88, a PEG ratio of 1.10 and a beta of 0.73. The stock has a fifty day moving average price of $19.43 and a 200 day moving average price of $18.30. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. Teva Pharmaceutical Industries has a 12 month low of $11.48 and a 12 month high of $22.80.

Insider Activity

In related news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Diversify Advisory Services LLC increased its position in Teva Pharmaceutical Industries by 2.5% in the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock worth $426,000 after purchasing an additional 496 shares during the last quarter. Sanctuary Advisors LLC increased its position in Teva Pharmaceutical Industries by 1.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock worth $601,000 after purchasing an additional 664 shares during the last quarter. Sequoia Financial Advisors LLC increased its position in Teva Pharmaceutical Industries by 0.7% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock worth $2,025,000 after purchasing an additional 805 shares during the last quarter. DGS Capital Management LLC increased its position in Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock worth $246,000 after purchasing an additional 872 shares during the last quarter. Finally, Smithfield Trust Co increased its position in Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Further Reading

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.